- $377.11m
- $371.38m
- $132.58m
- 92
- 28
- 50
- 58
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.09 | ||
| Price to Tang. Book | 7.3 | ||
| Price to Free Cashflow | 38.23 | ||
| Price to Sales | 2.73 | ||
| EV to EBITDA | 17.86 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.36% | ||
| Return on Equity | 4.81% | ||
| Operating Margin | 8.72% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 100.08 | 94.86 | 105.14 | 99.95 | 132.58 | 119.68 | 136.2 | 10.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +243.65 | -86.29 | +545.39 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Surmodics, Inc. is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The Company's segments include Medical Device and IVD. The Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral, coronary and structural heart. It manufactures vascular intervention medical devices, including drug-coated balloons, and radial access balloon catheters and guide sheaths. The IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Directors
- Susan Knight NEC (67)
- Gary Maharaj CEO (58)
- Timothy Arens CFO (54)
- Teri Sides SVP (52)
- Gordon Weber SVP (58)
- Joseph Stich SVP (56)
- Charles Olson SVP (57)
- Nusrath Sultana VPR (47)
- Jose Bedoya IND (65)
- David Dantzker IND (78)
- Lisa Heine IND (58)
- Ronald Kalich IND (74)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 27th, 1979
- Public Since
- March 4th, 1998
- No. of Shareholders
- 240
- No. of Employees
- 376
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 14,236,000
- Address
- 9924 W 74th St, EDEN PRAIRIE, 55344
- Web
- https://www.surmodics.com/
- Phone
- +1 9525007000
- Auditors
- Deloitte & Touche LLP
Upcoming Events for SRDX
Q2 2024 Surmodics Inc Earnings Release
Q3 2024 Surmodics Inc Earnings Release
Similar to SRDX
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the SurModics share price?
As of Today at 19:20 UTC, shares in SurModics are trading at $26.49. This share price information is delayed by 15 minutes.
How has the SurModics share price performed this year?
Shares in SurModics last closed at $26.49 and the price had moved by +11.73% over the past 365 days. In terms of relative price strength the SurModics share price has underperformed the S&P500 Index by -7.03% over the past year.
What are the analyst and broker recommendations for SurModics?
The overall consensus recommendation for SurModics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the SurModics dividend yield?
SurModics does not currently pay a dividend.
Does SurModics pay a dividend?
SurModics does not currently pay a dividend.
When does SurModics next pay dividends?
SurModics does not currently pay a dividend.
How do I buy SurModics shares?
To buy shares in SurModics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of SurModics?
As of the previous close price of $26.49, shares in SurModics had a market capitalisation of $377.11m.
Where are SurModics shares listed?
Here are the trading details for SurModics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: SRDX
What kind of share is SurModics?
Based on an overall assessment of its quality, value and momentum SurModics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a SurModics share price forecast for 2024?
The analyst consensus target price for shares in SurModics is $59.00. That is 122.73% above the last closing price of $26.49.
Analysts covering SurModics currently have a consensus Earnings Per Share (EPS) forecast of -$0.94 for the next financial year.
What is the trend in the SurModics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SurModics. Over the past six months, its share price has underperformed the S&P500 Index by -23.87%.
As of the last closing price of $26.49, shares in SurModics were trading -18.44% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the SurModics PE Ratio?
The SurModics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $26.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of SurModics?
SurModics' management team is headed by:
- Susan Knight - NEC
- Gary Maharaj - CEO
- Timothy Arens - CFO
- Teri Sides - SVP
- Gordon Weber - SVP
- Joseph Stich - SVP
- Charles Olson - SVP
- Nusrath Sultana - VPR
- Jose Bedoya - IND
- David Dantzker - IND
- Lisa Heine - IND
- Ronald Kalich - IND